Lisraya (brepocitinib) blocks TYK2- and JAK1-dependent cytokine signaling, reducing downstream STAT activation and inflammatory gene expression in dermatomyositis.
Related Analysis
Want the news story behind this science? Read my analysis of Lisraya’s FDA approval as the first oral treatment for adults with dermatomyositis.
Science at a Glance
Lisraya (brepocitinib) is a once-daily oral TYK2/JAK1 inhibitor approved by the FDA for adults with dermatomyositis. By inhibiting TYK2 and JAK1, Lisraya suppresses multiple inflammatory cytokine pathways that depend on either kinase. (FDA approval)
| Therapy | Company | Modality / Mechanism | Administration | Dermatomyositis status |
|---|---|---|---|---|
| Lisraya (brepocitinib) | Priovant / Roivant | TYK2/JAK1 inhibitor | Oral, once daily | FDA approved, 2026 |
| Octagam 10% | Octapharma | IVIG / broad immunomodulation | IV infusion | FDA approved, 2021 |
| Dazukibart | Pfizer | Anti-IFN-β antibody | IV biologic | Phase 3 |
Octagam 10% was approved for adult dermatomyositis in 2021, while Lisraya became the first approved oral targeted therapy for the disease.
Why JAK–STAT Signaling Matters in Dermatomyositis
Dermatomyositis is a systemic autoimmune disease characterized by inflammatory injury to the skin and skeletal muscle, causing characteristic rashes and muscle weakness.
A prominent molecular feature of dermatomyositis is increased type I interferon signaling, with interferon-stimulated genes strongly expressed in affected tissues. (Interferon signaling)
Multiple inflammatory cytokines signal through receptor-specific combinations of JAK-family kinases. Type I interferons use JAK1/TYK2, IFN-γ primarily uses JAK1/JAK2, and IL-12/23 signaling depends heavily on TYK2/JAK2. These pathways converge downstream on STAT transcription factors and inflammatory gene expression. (JAK–STAT biology)
How Lisraya Interrupts the Signal
Lisraya does not neutralize a single cytokine. Brepocitinib selectively inhibits TYK2 and JAK1, allowing it to suppress multiple inflammatory cytokine pathways that depend on either kinase. (Brepocitinib pharmacology)
In simplified form:
Inflammatory cytokines
→ receptor-specific JAK signaling
→ STAT activation
→ inflammatory gene expression
→ skin and muscle inflammation
Lisraya (brepocitinib) inhibits TYK2/JAK1-dependent signaling before STAT activation.
By reducing downstream STAT activation, Lisraya can interfere with several inflammatory pathways rather than blocking only one upstream cytokine.
Lisraya inhibits TYK2- and JAK1-dependent signaling, reducing downstream STAT activation and inflammatory gene expression.
Clinical Validation in VALOR
The Phase 3 VALOR trial randomized 241 adults with dermatomyositis to brepocitinib 30 mg, brepocitinib 15 mg or placebo for 52 weeks.
At Week 52, the mean Total Improvement Score was 46.5 with brepocitinib 30 mg versus 31.2 with placebo, demonstrating significantly greater overall disease improvement. The 30-mg dose also improved skin disease, muscle-related outcomes and steroid-sparing measures. (VALOR Phase 3)
The FDA-approved Lisraya regimen is 30 mg once daily.
Lisraya vs Octagam: Targeted Signaling vs Broad Immunomodulation
Lisraya and Octagam treat dermatomyositis through fundamentally different mechanisms.
| Lisraya | Octagam 10% | |
|---|---|---|
| Drug type | Small-molecule inhibitor | Human IVIG |
| Administration | Oral, once daily | IV infusion |
| Main approach | Targeted intracellular signaling inhibition | Broad immunomodulation |
| Main target | TYK2 / JAK1 | Multiple immune mechanisms |
| Downstream effect | STAT signaling ↓ | Broad modulation of antibodies, Fc receptors, complement and cytokine activity |
| FDA DM approval | 2026 | 2021 |
Octagam 10% is administered intravenously and broadly modulates immune activity, whereas Lisraya directly targets intracellular TYK2/JAK1 signaling. (FDA Octagam)
A More Selective Competitor Is Also Emerging
Pfizer’s dazukibart provides a more upstream mechanistic contrast.
Dazukibart is an anti-IFN-β monoclonal antibody that directly neutralizes interferon beta rather than inhibiting intracellular JAK signaling. After positive Phase 2 results, Pfizer advanced dazukibart into Phase 3 development for dermatomyositis and polymyositis. (Pfizer pipeline)
This creates three distinct therapeutic strategies:
Octagam → broad immune modulation
Dazukibart → upstream IFN-β blockade
Lisraya → downstream TYK2/JAK1 inhibition
BP Science View
Lisraya is scientifically interesting because it targets a shared intracellular signaling network rather than a single inflammatory cytokine. Dermatomyositis has a strong interferon signature, but several cytokines can contribute to disease through different JAK combinations.
That broader signaling coverage may help explain why TYK2/JAK1 inhibition improved both skin and muscle-related disease activity in VALOR. At the same time, Lisraya carries a boxed warning for serious infections, malignancy, major cardiovascular events and thrombosis. (FDA safety)
The competitive landscape is also becoming more differentiated. Lisraya offers oral targeted therapy, Octagam provides established broad immunomodulation, and dazukibart is testing whether a more selective upstream interferon blockade can provide comparable or better disease control.
About BP Science
BP Science explains the biology and mechanisms behind emerging biopharmaceutical technologies, connecting molecular science with clinical and competitive development.
Have a question about my interpretation or another angle you’d like to discuss? Leave a comment — I’d be happy to hear your thoughts.
Leave a Reply